SV| IntelligenceTherapeutics · Institutional intelligence for biotech investing and company creation
The relationship graph
Network
Three decades of relationships across academia, industry and the SV portfolio. The value is not the list of names — it is knowing the warmest route to the person behind a development, and who at SV owns it. Switch strategy to see how Atlas constructs a different ecosystem for each investment domain.
EdgesKnown SV relationshipScientific ecosystem relationshipIllustrative / demo relationship
Select any node
Hover to trace a relationship. Click a person, company or institution to see why it matters — and the warmest route SV already has to reach it.
SV Life SciencesUniversity / institutionResearcher / investigatorSV portfolio companyCompany / spinoutFounderScientific adviserPharma / strategicCo-investorScientific concept / programme
Relationship intelligence
The ecosystem, as a directory
The same biotech / oncology ecosystem, listed as supporting detail. The graph above is the primary view — this is for scanning. Dots show provenance: live/public, derived, or illustrative.
People
- Oxford PI — tumour immunology — Principal Investigator (illustrative role)
- Oxford translational lead — Translational lead (illustrative role)
- Cambridge group leader — DDR — Group leader (illustrative role)
- Cambridge translational researcher — Translational researcher (illustrative role)
- Crick group leader — immunometabolism — Group leader (illustrative role)
- Crick postdoc → founder — Founder (illustrative role)
- Edinburgh cell-therapy researcher — Researcher (illustrative role)
- Founder — Enara — Founder (illustrative role)
- Founder — Quell — Founder (illustrative role)
- SAB — immuno-oncology — Scientific advisory board member (illustrative role)
- SAB — cell therapy — Scientific advisory board member (illustrative role)
Institutions
- University of Oxford
- Oxford University Innovation
- University of Cambridge
- Cambridge Enterprise
- Francis Crick Institute
- Cancer Research UK
- CRUK Therapeutic Discovery
- University of Edinburgh
Companies
- Mestag Therapeutics — SV portfolio company
- Enara Bio — SV portfolio company
- Quell Therapeutics — SV portfolio company
- Artios Pharma — SV portfolio company
- Roche / Genentech
- AstraZeneca
- MSD
Investors
- SV Life Sciences — Life-sciences venture firm
- Kate Bingham — Managing Partner, SV
- SV biotech team — Investment team
- Syncona
- Sofinnova Partners
- Cambridge Innovation Capital
Science
- Tumour-specific antigen
- Immunometabolism
- Engineered Treg
- DNA-damage response
- Antibody-discovery platform